{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T18:14:11Z","timestamp":1781115251936,"version":"3.54.1"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":4376,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1997,5]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Recombinant erythropoietin (r\u2010EPO) was administered to 37 patients with advanced, transfusion\u2010dependent and chemo\u2010resistant multiple myeloma (MM), at the fixed dose of 10,000\/U s.c, 3 times a week, for 2 months. Thirteen patients (35.1%) achieved a significant response in terms of complete abolition of red cell transfusions. Factors significantly predictive of response were: a) inappropriate production of endogenous EPO, as expressed by a reduced observed\/predicted ratio; b) presence of a consistant number of circulating erythroid precursors BFU\u2013E; c) low serum levels of tumor necrosis factor (TNF) and interleukin\u20101 (IL\u20101), cytokines with inhibitory activity on erythropoiesis; d) a single line of previously received chemotherapy. Renal failure, bone marrow plasma cell infiltration, serum levels of IL\u20106 and other main clinical and laboratory parameters did not affect significantly the response to r\u2010EPO. High fluorescence reticulocytes (HFR) and soluble transferrin receptor (sTfR) values were useful to detect an early stimulation of erythropoiesis in responders, while a high percentage of circulating hypochromic erythrocytes (HE), as assessed by an automated counter, identified those patients developing functional iron deficiency during r\u2010EPO treatment. We conclude that about one\u2010third of severely anemic patients with advanced MM, unresponsive to chemotherapy, may benefit by r\u2010EPO therapy. The clinical management of these patients can be accomplished using non\u2010invasive parameters, such as sTfR, HFR and HE.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1997.tb01677.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T08:11:21Z","timestamp":1279440681000},"page":"314-319","source":"Crossref","is-referenced-by-count":38,"title":["Clinical results of recombinant erythropoietin in transfusion\u2010dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis"],"prefix":"10.1111","volume":"58","author":[{"given":"Pellegrino","family":"Musto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"D'Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Potito Rosario","family":"Scalzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Marta","family":"Minervini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina Francesca","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Modoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"29","article-title":"Multiple myeloma. Review of 869 cases","volume":"50","author":"Kyle RA.","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90020-E"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1982.141"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059639"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb00031.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309148523"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb02976.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb06939.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30344-7"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb06330.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1991.tb17252.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116178"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199006143222402"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1065126"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1991.tb00287.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma and non\u2010Hodgkin's lymphoma: dose finding and identification of predictors of response","volume":"86","author":"Cazzola M","year":"1995","journal-title":"Blood"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.5530110203"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.5530110502"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/archinte.1995.00430190059008","article-title":"Epoetin alfa for the treatment of the anemia of multiple myeloma: a prospective, randomized, placebo\u2010controlled, double blind trial","volume":"155","author":"Garton JP","year":"1995","journal-title":"Arch Int Med"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01696618"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","article-title":"Recombinant human erythropoietin in transfusion\u2010dependent anemic patients with multiple myeloma and non\u2010Hodgkin's lymphoma: a randomized multicenter study","volume":"87","author":"Ostemborg A","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_23_2","first-page":"315","article-title":"Safety and efficacy of recombinant human erythropoietin in treatment of anemia associated with multiple myeloma in hemo\u2010dialysed patients","volume":"8","author":"Ruedin P","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb08133.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood.V80.3.841.841","article-title":"Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders","volume":"80","author":"Cazzola M","year":"1992","journal-title":"Blood"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.6.1955.1955"},{"key":"e_1_2_1_27_2","first-page":"1","article-title":"The soluble transferrin receptor: biological aspects and clinical usefulness as quantitative measure of erythropoiesis","volume":"77","author":"Beguin Y.","year":"1992","journal-title":"Haematologica"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.44.2.130"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6821.225"},{"key":"e_1_2_1_30_2","first-page":"205","volume-title":"Colture of Hematopoietic Cells","author":"Hatzfeld J","year":"1994"},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.V81.4.1067.1067","article-title":"Quantitative assessement of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptors and erythropoietin","volume":"81","author":"Beguin Y","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_32_2","first-page":"928","article-title":"Tumor necrosis factor\u2010alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU\u2010E and BFU\u2010E and the hematopoietic cell lines K562, HL60 and HEL cells","volume":"15","author":"Roodman GD","year":"1987","journal-title":"Exp Hematol"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19871215)60:12<2965::AID-CNCR2820601219>3.0.CO;2-O"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.V73.3.678.678","article-title":"In vivo hematopoietic effects of recombinant interleukin\u20101\u2010alpha in mice: stimulation of granulocytic, monocytic, megacaryocytic and early erythroid progenitors, suppression of late\u2010stage erythropoiesis, and reversal of erythroid suppression with erythropoietin","volume":"73","author":"Johnson GS","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041500109"},{"key":"e_1_2_1_36_2","first-page":"265","article-title":"Low serum levels of tumor necrosis factor and interleukin\u20101\u03b2 in myelodysplastic syndromes responsive to recombinant erythropoietin","volume":"79","author":"Musto P","year":"1994","journal-title":"Haematologica"},{"key":"e_1_2_1_37_2","doi-asserted-by":"crossref","first-page":"14572","DOI":"10.1016\/S0021-9258(18)77341-9","article-title":"Transitional control during the acute phase response. Ferritin synthesis in response to interleukin\u20101","volume":"265","author":"Rogers JT","year":"1990","journal-title":"J Biol Chem"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.11.4946"},{"key":"e_1_2_1_39_2","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1182\/blood.V75.11.2150.2150","article-title":"Effects of interleukin\u20106 on fetal hematopoietic progenitors","volume":"75","author":"Gardner JD","year":"1990","journal-title":"Blood"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.499"},{"key":"e_1_2_1_41_2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood.V86.4.1288.bloodjournal8641288","article-title":"Interleukin\u20106\u2010associated anemia: determination of the underlying mechanisms","volume":"151","author":"Atkins MB","year":"1995","journal-title":"Blood"},{"key":"e_1_2_1_42_2","first-page":"493","article-title":"Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes","volume":"79","author":"Musto P","year":"1994","journal-title":"Haematologica"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.1.29.29"},{"key":"e_1_2_1_44_2","first-page":"434","article-title":"Prediction of response to recombinant human erythropoietin in anemia of malignancy","volume":"81","author":"Cazzola M","year":"1996","journal-title":"Haematologica"},{"key":"e_1_2_1_45_2","first-page":"526","article-title":"Guidelines for the use of recombinant human erythropoietin","volume":"79","author":"Barosi G","year":"1994","journal-title":"Haematologica"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1997.tb01677.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1997.tb01677.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T06:41:42Z","timestamp":1698388902000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1997.tb01677.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1997,5]]}},"alternative-id":["10.1111\/j.1600-0609.1997.tb01677.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1997.tb01677.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,5]]}}}